Citi Upgrades Merus N.V. (MRUS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St flat as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- The real reason Meta shares are surging has nothing to do with its new AI model
Merus (MRUS) PT Doubled to $32 at Wedbush Amid Incyte Deal
December 21, 2016 11:50 AM ESTWedbush analyst David Nierengarten raised his price target on Outperform-rated Merus N.V. (NASDAQ: MRUS) to $32.00 (from $16.00) after the company and Incyte announced a collaboration to develop up to eleven bispecific antibody research programs using MRUSs Biclonics platform, including two of MRUSs current preclinical... More
Merus N.V. (MRUS) Surges 50% on Incyte (INCY) Collaboration
December 21, 2016 8:15 AM ESTMerus N.V. (NASDAQ: MRUS) surges 51% in pre-open trade after the company and Incyte Corporation (NASDAQ: INCY) entered into a global,... More
Merus N.V. (MRUS) and Incyte (INCY) Announce Research Collaboration
December 21, 2016 7:02 AM ESTIncyte Corporation (NASDAQ: INCY) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and development of bispecific antibodies utilizing Merus proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus current preclinical immuno-oncology discovery programs.
Biclonics® retain the IgG format of antibodies that are produced naturally by the immune system and, by binding to two targets, enable multiple modes of... More
